Coeptis Therapeutics (OTC PINK: COEP) has raided the nearby University of Pittsburgh in the latest step towards realizing the company’s aim of disrupting conventional treatment paradigms.
The Pennsylvania, USA-based firm has announced an exclusive license deal with the university for the rights to a chimeric antigen receptor T cell (CAR-T) technology – SNAP-CAR –designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.
"SNAP-CAR may offer the potential to mitigate the toxicity of CAR-T therapy by allowing clinicians to control the adaptor dose"Completion of the exclusive license agreement for SNAP-CAR follows Coeptis’ entry into an option agreement with the university, which was announced in May.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze